By HealthDataConsortium.org Research Team
Cannabigerol, usually shortened to CBG, is sold as a gummy, tincture, or capsule with promises ranging from calmer moods to better sleep to pain relief. The marketing is confident. The human research is not — at least not yet. Here is what the small number of controlled human studies on CBG actually measured, what they found, and where the evidence stops.
What Early Human Studies Show
Until 2024, there were no published placebo-controlled human trials of CBG alone. That changed with a double-blind, placebo-controlled, crossover trial out of Washington State University and UCLA, published in Scientific Reports. Researchers gave 34 healthy, experienced cannabis users a single 20 mg dose of hemp-derived CBG and compared it to a placebo.
The results, measured at 20, 45, and 60 minutes after dosing:
- CBG produced a statistically significant reduction in self-reported anxiety and stress compared to placebo.
- Participants showed improved verbal memory recall after taking CBG.
- CBG did not cause intoxication, motor impairment, or cognitive impairment — and did not produce the heart palpitations or dry mouth sometimes reported with THC.
- Mood itself was not significantly improved. Earlier anecdotal and survey-based reports of CBG having antidepressant effects were not supported in this controlled setting.
The study’s own authors were explicit about the limits of what they’d found, writing that researchers “need to avoid claims that CBG is a miracle drug.” They flagged several constraints on the result: the trial used experienced cannabis users rather than a general population, tested one modest dose, and was conducted remotely rather than in a lab. A follow-up trial is now underway at Washington State University to replicate the findings, add physiological measures like cortisol and heart rate, and test non-cannabis users.
A separate line of research looked at a different question entirely: how CBG behaves in the body. A Phase 1 human study published in the Journal of Pharmacology and Experimental Therapeutics gave 12 healthy adults ascending single doses of CBG (0, 25, 50, 100, and 200 mg) to measure safety, tolerability, and pharmacokinetics — essentially, how much CBG gets absorbed and how the body processes it. CBG was generally well tolerated at these single doses in this small group. That study was explicit that it tested acute, single-dose safety only; it did not test whether CBG treats any condition, and it says nothing about what happens with repeated, long-term use.
Which Disease Claims Remain Untested
This is the part sellers tend to skip. Two gaps matter most for anyone evaluating a CBG product’s marketing claims.
The research is almost entirely preclinical. Laboratory and animal studies have looked at CBG for inflammation, pain signaling, appetite, and blood pressure, among other things. None of that is the same as evidence that CBG does these things in people. Preclinical findings generate hypotheses for human research — they are not a substitute for it, and a supplement label that cites “studies show CBG reduces inflammation” is very likely leaning on animal or cell-culture data, not a human trial.
The pain and recovery claim gets attributed to the wrong ingredient. One pilot study, published in the Journal of the International Society of Sports Nutrition, did find a treatment effect on muscle soreness after exercise-induced damage. But the product tested wasn’t CBG — it was a five-ingredient formula combining CBD (35 mg), CBG (50 mg), the terpene beta-caryophyllene (25 mg), branched-chain amino acids (3.8 g), and magnesium citrate (420 mg) in 40 participants. Because CBG was one ingredient among five, this study cannot tell you what CBG alone contributed to the result, if anything. If you see this study cited as proof that “CBG relieves muscle soreness,” that’s a misreading of what was actually tested.
Beyond those two gaps: no published controlled human trial has tested CBG for a diagnosed anxiety disorder, chronic pain condition, inflammatory disease, or any other clinical condition. The 2024 anxiety trial tested healthy adults’ acute stress response — not patients with a clinical diagnosis. The authors’ own stated next step is extending the research “to a clinical population of patients with anxiety disorders,” which signals that step has not been taken yet.
On regulatory status: the FDA has not approved any over-the-counter CBG product for any use. The agency has approved exactly one cannabis-derived drug, Epidiolex, a purified CBD formulation prescribed for specific seizure syndromes in patients one year and older — and that approval says nothing about CBG, and nothing about retail supplements generally. Outside of that single prescription drug, the FDA has stated plainly that cannabis-derived products sold online or in stores “have not been evaluated as to whether they work, what the proper dosage may be if they do work, how they could interact with other drugs, or whether they have dangerous side effects.”
Evidence Worksheet: CBG Benefits Claims
Use this to check any specific CBG claim against what was actually tested, who it was tested in, and what’s still unknown.
- Claim: CBG reduces anxiety and stress.
- Source type: one placebo-controlled human crossover trial, 34 participants
- Evidence limit: single 20 mg dose, experienced cannabis users only, remote testing conditions, not yet replicated
- Unresolved question: does the effect hold in non-cannabis users, at other doses, or with repeated use?
- Next step: check whether the Washington State University replication trial, recruiting as of this writing, has published results
- Claim: CBG improves memory.
- Source type: the same single trial above
- Evidence limit: one measurement window, one trial, mechanism not established
- Unresolved question: is this a repeatable effect or a single-study finding?
- Next step: look for independent replication before treating this as settled
- Claim: CBG is safe.
- Source type: a Phase 1 pharmacokinetic study, 12 healthy adults, single ascending doses up to 200 mg
- Evidence limit: small sample, single doses only, healthy adults only
- Unresolved question: what happens with daily use over weeks or months?
- Next step: ask any product maker for repeated-dose safety data specific to their product, not just this single-dose study
- Claim: CBG relieves muscle soreness.
- Source type: a pilot trial of a five-ingredient blend (CBD, CBG, beta-caryophyllene, BCAAs, magnesium), not CBG alone
- Evidence limit: CBG’s individual contribution cannot be separated from the other four ingredients
- Unresolved question: does CBG alone, at any dose, affect muscle recovery?
- Next step: treat this claim as unsupported for CBG specifically until a CBG-only trial exists
- Claim: CBG fights inflammation, pain, or high blood pressure.
- Source type: preclinical animal and cell-culture studies only
- Evidence limit: no human trial has tested these outcomes for CBG
- Unresolved question: do any of these effects translate to people, and at what dose?
- Next step: treat these as research hypotheses, not established benefits, until human trials exist
Reading Study Limitations Before You Talk to a Clinician
If you’re weighing whether to try a CBG product, the honest starting point is that acute, single-dose research in healthy volunteers tells you something about short-term tolerability and a possible stress response — it does not validate a specific retail product, a specific dose for daily use, or any disease claim. A pilot study showing a “treatment difference” is not the same as a confirmed treatment. Before discussing options with a clinician, it’s worth reading the actual limitations sections of the studies above rather than a brand’s summary of them — the researchers themselves are the most reliable source on what their data does and doesn’t support.
For more on evaluating a seller’s own research claims, see our guide to spotting overstated or unsupported CBD and hemp product claims. For how broad-spectrum and full-spectrum labeling affects what’s actually in a bottle, see CBD labels and drug tests: what the terms do and don’t tell you.
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
